

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1 Attorney Docket Number 02-329-A

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (<i>if known</i>)			
	*				

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (<i>if known</i>)				
/D.C./	*1.	WO 00/47618 A	08/18/2000	Anderson et al.		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
/D.C./	*2.	Cai et al., "Society for Neuroscience Abstracts", (2000) - Vol. 26: Abstract No. 276.4.	
	*3.	Cai et al., "Nature Neuroscience", (2001) - Vol. 4(3): pgs. 233-234.	
	*4.	Citron, "Molecular Medicine Today", (2000) - Vol. 6: pgs. 392-397.	
	*5.	Hardy, Trends in Neurosciences, (1997) Vol. 20(4), pgs. 154-159	
	*6.	Rodriguez et al., "Nature Genetic", (2000) - Vol. 25: pgs. 139-140.	
/D.C./	*7.	Luo et al., "Nature Neuroscience", (2001) - Vol. 4(3): pgs. 231-232.	

Examiner Signature	/Deborah Crouch/	Date Considered	06/10/2007
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of U.S. Patent Documents at www.uspto.gov or MPEP 801.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Form PTO-1449 (modified)

Atty. Docket No.
MBHB02-329-ASerial No.
10/082,804**List of Patents and Publications for Applicant's****INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1 & 2

Other Art

See Page 2, 3 & 4

**U.S. Patent Documents**

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
dc	A1	4,666,829	05/19/1987	Glenner et al.			
	A2	5,612,486	03/18/1997	McConlogue, et al.			
	A3	5,811,231	09/22/1998	Farr et al.			
	A4	6,040,138	03/21/2000	Lockhart et al.			
	A5	6,114,133	09/05/2000	Seubert et al.			
dc	A6	6,204,061	03/20/2001	Capecci et al.			

U.S. Patent Applications

Exam. Init.	Ref. Des	Application Number	Filing Date	Name			
6/19/07 dc	A7	60/271,092	02/23/2001	Gurney			
	A8	60/271,514	02/26/2001	McConlogue			
	A9	60/293,762	05/25/2001	Gurney			

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
dc	B1	WO 97/07669	03/06/1997	PCT International			
	B2	WO 98/30683	07/16/1998	PCT International			
	B3	WO 98/37183	08/27/1998	PCT International			
	B4	WO 98/39416	09/11/1998	PCT International			
dc	B5	WO 99/37143	07/29/1999	PCT International			

EXAMINER: *Dorothy Cronin*DATE CONSIDERED: *6/19/07*

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.
MBHB02-329-ASerial No.
10/082,804

**List of Patents and Publications for Applicant's
INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

U.S. Patent Documents
*See Page 1*Foreign Patent Documents
*See Page 1 & 2*Filing Date:
February 22, 2002Group:
1645Other Art
*See Page 2, 3 & 4***RECEIVED**

AUG 21 2002

TECH CENTER 1600/2000

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
de	B6	WO 00/17369	03/30/2000	PCT International			
de	B7	WO 00/72880	12/07/2000	PCT International			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
de	C1	International Search Report from PCT/US02/05639.
de	C2	Acquati et al., "The gene encoding DRAP (BACE2), a glycosylated transmembrane protein of the aspartic protease family, maps to the Down critical region," <u>FEBS Letters</u> 468(1):59-64 (2000).
	C3	Altschul et al., "Basic Local Alignment Search Tool," <u>J. Mol. Biol.</u> 215:403-410 (1990).
	C4	Borchelt et al., "Accelerated Amyloid Deposition in the Brains of Transgenic Mice Coexpressing Mutant Presenilin 1 and Amyloid Precursor Proteins," <u>Neuron</u> 19:939-945 (1997).
	C5	Bradley et al., "Formation of germ-line chimaeras from embryo-derived teratocarcinoma cell lines," <u>Nature</u> 309:255-256 (1984).
	C6	De Strooper et al., "Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein," <u>Nature</u> 391:387-390 (1998).
	C7	Farzan et al., "BACE2, a β -secretase homolog, cleaves at the β site and within the amyloid- β region of the amyloid- β precursor protein," <u>Proc. Nat'l. Acad. Sci.</u> 97(17):9712-9717 (2000).
	C8	Glenner & Wong, "Alzheimer's Disease and Down's Syndrome: Sharing of a Unique Cerebrovascular Amyloid Fibril Protein," <u>Biochemical and Biophysical Research Communications</u> 120:1131 (1984).
de	C9	Hardy et al., "Amyloid, the presenilins and Alzheimer's disease," <u>TINS</u> 20:154-159 (1997).

EXAMINER: Debra A. Lynch DATE CONSIDERED: 6/19/07

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

RECEIVED

FEB 20 2002
U.S. PATENT & TRADEMARK OFFICE
3000
445 81 2002

Form PTO-1449 (modified)

Atty. Docket No.
MBHB02-329-A

Serial No.
10/082,804

List of Patents and Publications for Applicant's
INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)

U.S. Patent Documents
See Page 1

Foreign Patent Documents
See Page 1 & 2

Filing Date:
February 22, 2002

Group:
1645

Other Art
See Page 2, 3 & 4

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
dc	C10	Henikoff & Henikoff, "Amino acid substitution matrices from protein blocks," <u>Proc. Nat'l. Acad. Sci. USA</u> 89:10915-10919 (1992).
	C11	Hsiao et al., "Correlative Memory Deficits, A β Elevation, and Amyloid Plaques in Transgenic Mice," <u>Science</u> 274:99-102 (1996).
	C12	Huber et al., "cDNA Cloning and Molecular Characterization of Human Brain Metalloprptease MP100: A β -Secretase Canadidate?" <u>Journal of Neurochemistry</u> 72:1215-1223 (1999).
	C13	Jaenisch et al., "Transgenic animals," <u>Science</u> 240:1468-1474 (1988).
	C14	Johnson-Wood et al., "Amyloid precursor protein processing and A β_{42} deposition in a transgenic mouse model of Alzheimer disease," <u>Proc. Nat'l. Acad. Sci. USA</u> 94:1550-1555 (1997).
	C15	Kang et al., "The Precursor of Alzheimer's Disease Amyloid A4 Protein Resembles a Cell-Surface Receptor," <u>Nature</u> 325:733-736 (1987).
	C16	Karlin & Altschul, "Applications and statistics for multiple high-scoring segments in molecular sequences," <u>Proc. Nat'l. Acad. Sci. USA</u> 90:5873-5787 (1993).
	C17	Kitaguchi et al., "Novel precursor of Alzheimer's disease amyloid protein shows protease inhibitory activity," <u>Nature</u> 331:530 (1988).
	C18	Lai et al., "Production of α -1, 3-Galactosyltransferase Knockout Pigs by Nuclear Transfer Cloning," <u>Science</u> 295:1089-1092 (2002).
	C19	Needleman & Wunsch., "A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins," <u>J. Mol. Biol.</u> 48:443 (1970).
	C20	Pearson & Lipman, "Improved tools for biological sequence comparison," <u>Proc. Nat'l. Acad. Sci. USA</u> 85:2444-2448 (1988).
	C21	Ponte et al., "A New A4 Amyloid mRNA contains a domain homologous to serine proteinase inhibitors," <u>Nature</u> 331:525-527 (1988).
dc	C22	Roberds et al., "BACE knockout mice are healthy despite lacking the primary β -secretase activity in brain: implications for Alzheimer's disease therapeutics," <u>Human Molecular Genetics</u> 10:1317-1324 (2001).

EXAMINER:

Dale or Dale Cind

DATE CONSIDERED: 6/19/07

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

Atty. Docket No.
MBHB02-329-ASerial No.
10/082,804

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant
McConlogue et al.

RECEIVED

AUG 21 2002

TECH CENTER 1600

U.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 1 & 2Group:
1645
Other Art
See Page 2, 3

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>de</i>	C23	Roger et al., "Behavioral and functional analysis of mouse phenotype: SHIRPA, a proposed protocol for comprehensive phenotype assessment," <u>Mamm. Genome</u> 8:711-713 (1997).
	C24	Selkoe et al., "Normal and Abnormal Biology of the β -Amyloid Precursor Protein," <u>Annual Rev. Neurosci</u> 17:489-517 (1994).
	C25	Sinha et al., "Cellular mechanisms of β -amyloid production and secretion," <u>Proc. Natl. Acad. Sci. USA</u> 96:11049-11053 (1999).
	C26	Sinha et al., "Purification and cloning of amyloid precursor protein β -secretase from human brain," <u>Nature</u> 402:537-540 (1999).
	C27	Smith & Waterman, "Comparison of Biosequences," <u>Adv. Appl. Math.</u> 2:482 (1981).
	C28	Sturchler-Pierrat et al., "Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology," <u>Proc. Nat'l. Acad. Sci. USA</u> 94:13287-13292 (1997).
	C29	Vassar et al., " β -Secretase Cleavage of Alzheimer's Amyloid Precursor Protein by the Transmembrane Aspartic Protease BACE," <u>Science</u> 286:735-741 (1999).
	C30	Wattler et al., "Construction of Gene Targeting Vectors from λ KOS Genomic Libraries," <u>Biotechniques</u> 26:1150-1160 (1999).
<i>de</i>	C31	Yan et al., "Membrane-anchored aspartyl protease with Alzheimer's disease β -secretase activity," <u>Nature</u> 402:533-537 (1999).

EXAMINER:

Deborah Amdt

DATE CONSIDERED:

6/19/02

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

Atty. Docket No.
MBHB02-329-ASerial No.
10/082,804

**List of Patents and Publications for Applicant's
INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

Applicant
McConlogue et al.Filing Date:
February 22, 2002Group:
1645U.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 1 & 2Other Art
See Page 2, 3**RECEIVED**

TECH CENTER 1600

AUG 21 2002

**Other Art (Including Author, Title, Date Pertinent Pages, Etc.)**

Exam. Init.	Ref. Des.	Citation
	C23	Roger et al., "Behavioral and functional analysis of mouse phenotype: SHIRPA, a proposed protocol for comprehensive phenotype assessment," <u>Mamm. Genome</u> 8:711-713 (1997).
	C24	Selkoe et al., "Normal and Abnormal Biology of the β -Amyloid Precursor Protein," <u>Annual Rev. Neurosci</u> 17:489-517 (1994).
	C25	Sinha et al., "Cellular mechanisms of β -amyloid production and secretion," <u>Proc. Natl. Acad. Sci. USA</u> 96:N1049-11053 (1999).
	C26	Sinha et al., "Purification and cloning of amyloid precursor protein β -secretase from human brain," <u>Nature</u> 402:537-540 (1999).
	C27	Smith & Waterman, "Comparison of Biosequences," <u>Adv. Appl. Math.</u> 2:482 (1981).
	C28	Sturchler-Pierrat et al., "Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology," <u>Proc. Nat'l. Acad. Sci. USA</u> 94:13287-13292 (1997).
	C29	Vassar et al., " β -Secretase Cleavage of Alzheimer's Amyloid Precursor Protein by the Transmembrane Aspartic Protease BACE," <u>Science</u> 286:735-741 (1999).
	C30	Wattler et al., "Construction of Gene Targeting Vectors from λ KOS Genomic Libraries," <u>Biotechniques</u> 26:1150-1160 (1999).
	C31	Yan et al., "Membrane-anchored aspartyl protease with Alzheimer's disease β -secretase activity," <u>Nature</u> 402:533-537 (1999).

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete if Known

Application No.	10/082,804
Filing Date:	February 22, 2002
First Named Inventor	McConlogue et al.
Art Unit	1632
Examiner Name	Crouch, Deborah

Sheet	1	of	Attorney Docket Number	02-329-A
-------	---	----	------------------------	----------

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (<i>if known</i>)			
*					

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (<i>if known</i>)				
*1.		WO 00/47618 A	08/18/2000	Anderson et al.		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
*2.		Cai et al., "Society for Neuroscience Abstracts", (2000) - Vol. 26: Abstract No. 276.4.	
*3.		Cai et al., "Nature Neuroscience", (2001) - Vol. 4(3): pgs. 233-234.	
*4.		Citron, "Molecular Medicine Today", (2000) - Vol. 6: pgs. 392-397.	
*5.		Hardy, Trends in Neurosciences, (1997) Vol. 20(4), pgs. 154-159	
*6.		Rodriguez et al., "Nature Genetic", (2000) - Vol. 25: pgs. 139-140.	
*7.		Luo et al., "Nature Neuroscience", (2001) - Vol. 4(3): pgs. 231-232.	

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.87 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.